Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 30, 2025 17:17 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

HANOVER, Md, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
August 28, 2024 08:00 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Provides Product Pipeline and Financial Update

Phase 2 trial with NGC-Cap in breast cancer underway NGC-Cap Phase 1b trial demonstrated a favorable safety profile with preliminary anti-tumor activity Preclinical studies demonstrated NGC-Iri...
February 21, 2024 08:15 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

HANOVER, MD, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
January 18, 2024 07:45 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split

HANOVER, MD, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
January 02, 2024 17:06 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals to Present at the Biotech Showcase 2024

HANOVER, MD, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
December 19, 2023 09:00 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine

FDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FU Interim analysis of the NGC-Cap Phase 1b data shows improved...
November 29, 2023 08:15 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook

HANOVER, MD, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next...
September 06, 2023 08:15 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

HANOVER, MD, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...